A Randomized, Prospective Phase III Comparison of Paclitaxel-Carboplatin Versus Docetaxel-Carboplatin as First Line Chemotherapy in Stage Ic-IV Epithelial Ovarian Cancer

Trial ID #	NCT00003998; SCOTROC
Phase	III
Drug Class	Chemotherapy
Drug Name	Docetaxel
Alternate Drug Names	Taxotere
Drugs in Trial	Carboplatin, Docetaxel, Paclitaxel
Eligible Participant	Newly diagnosed stage IC-IV ovarian cancer
Patients Enrolled	1050
Therapy Setting	First-line
Study Design	Randomized
Endpoints	ORR, PFS, OS, evaluated per RECIST
Efficacy	CarboPt+Pac (n=538) vs CarboPt+Doc (n=539): ORR: 59.5 vs 58.7% PFS: 14.8 vs 15.0 months, HR: 0.97 (0.83-1.13, p=0.707) 2-year survival rates: 68.9 vs 64.2%, HR: 1.13 (0.92-1.39, p=0.238)
Clinically Significant Adverse Events	CarboPt+Pac vs CarboPt+Doc: Serious AE: Grade 3-4 AE: neutropenia (84 vs 94%) Grade 2-4 AE: neurosensory toxicity (30 vs 11%), neuromotor toxicity (7 vs 3%)
Conclusion	Carboplatin+docetaxel is similar to carboplatin+paclitaxel in terms of response rates and PFS and OS
Reference	Vasey PA et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst (2014) 96(22):1682-91 https://pubmed.ncbi.nlm.nih.gov/15547181/